Search Articles

Found 1,054 articles

  • Bone Therapeutics appoints Lieve Creten as interim

    Bone Therapeutics appoints Lieve Creten as interim Chief Financial Officer

    • 21 Sep 2021
    • Editor

    BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed Lieve Creten, as interim Chief Financial Officer (CFO), succeeding Jean-Luc Vandebroek.

  • Amphista Therapeutics Appoints New Chairman, Joshu

    Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

    • 21 Sep 2021
    • Editor

    Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of Josh’s calibre to the Board.

  • Rentschler Biopharma appoints Dr. Christian Schett

    Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

    • 21 Sep 2021
    • Editor

    Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer (CSO) of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021. In this position, he will be working with a team of experienced scientists to ensure Rentschler Biopharma's continued technological and scientific leadership.

  • Bayer launches transparency register for scientifi

    Bayer launches transparency register for scientific collaborations with external partners

    • 17 Sep 2021
    • Editor

    Bayer AG is the first company in the future DAX-40-index to introduce a transparency register. The Bayer Science Collaboration Explorer is aimed at improving long-term public confidence in science and research. The database (bayer.com/bsce) provides access to new contract-based scientific collaborations with universities, public research institutions and individuals in Germany.

  • New Merck Group Function “Corporate Sustainability

    New Merck Group Function “Corporate Sustainability, Quality and Trade Compliance” established to cater to increasing ESG expectations

    • 17 Sep 2021
    • Editor

    Merck, a leading science and technology company, today announced that Petra Wicklandt will take over the leadership of the new Merck Group Function “Corporate Sustainability, Quality and Trade Compliance”, effective October 2021. It will cover all Environment, Health, Safety, Quality and Regulatory Compliance aspects at a corporate level.

  • NHS begins COVID-19 booster vaccination campaign

    NHS begins COVID-19 booster vaccination campaign

    • 17 Sep 2021
    • Editor

    The NHS has started delivering COVID booster jabs to people in eligible groups from today, as the biggest and most successful vaccination programme in health service history moves to the next stage.

  • Novavax to Participate in University of Oxford Com

    Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

    • 17 Sep 2021
    • Editor

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 3 (Com-COV3), led by the University of Oxford and funded by the UK Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR).

  • Boehringer Ingelheim Enters Clinical Collaboration

    Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

    • 17 Sep 2021
    • Editor

    Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer.

  • NICE Recommends MSD's KEYTRUDA® (pembrolizumab) Co

    NICE Recommends MSD's KEYTRUDA® (pembrolizumab) Combined with Chemotherapy as a First-Line Treatment for Certain Patients with Oesophageal Cancer

    • 17 Sep 2021
    • Editor

    MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) has today announced that the National Institute for Health and Care Excellence (NICE) has approved the use of pembrolizumab – MSD’s checkpoint inhibitor immunotherapy – in combination with platinum- and fluoropyrimidine-based chemotherapy as an option for untreated locally advanced unresectable (inoperable) or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma.

  • Median Technologies has been confirmed as a prefer

    Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

    • 17 Sep 2021
    • Editor

    Median Technologies (ALMDT:PA) announced today that the company has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world and selected to implement their clinical trial imaging strategy on some key oncology indications. As part of the confidentiality agreement, Median Technologies cannot disclose the name of the client nor the terms of the agreement.

  • AAV reference material to be produced at the Cell

    AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and Control

    • 17 Sep 2021
    • Editor

    The government funded project, supported by the department of Business, Energy & Industrial Strategy (BEIS) is a collaboration between the Cell and Gene Therapy Catapult (CGT Catapult) and the National Institute of Biological Standards and Control (NIBSC) and will result in preparing the first reference material of an Adenovirus-associated vector that will be globally available to facilitate harmonisation of modern analytics.

  • SHEPHERD Therapeutics Presents First Public Data a

    SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients

    • 17 Sep 2021
    • Editor

    SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.

  • HMNC Brain Health Initiates Pioneering Precision T

    HMNC Brain Health Initiates Pioneering Precision Therapy Program in Mental Health

    • 17 Sep 2021
    • Editor

    HMNC Brain Health, (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, has entered a definitive agreement to initiate a clinical phase II proof-of-concept program for its Nelivabon Project, targeting the 30% of Major Depressive Disorder (MDD) related to a dysfunction in the human body’s stress system with a completely novel mode of action.

  • Why You Should Takes Notes After a Job Interview

    Why You Should Take Notes After a Job Interview

    • 17 Sep 2021
    • Lucy Walters

    After your next pharma job interview, take the time to make notes on how you did and what you learnt. Write down any questions you answered well or struggled with, what you learnt about the role, what you learnt about the company, and what you learnt about your interviewer. You could also write down the questions you were asked, and anything your interviewer seemed particularly impressed with.

  • 2021 PM Society Digital Awards - Winners Announced

    2021 PM Society Digital Awards - Winners Announced

    • 17 Sep 2021
    • Editor

    The Digital Awards is in its 12th year and celebrates the best in digital communications within the pharmaceutical and healthcare sectors. Judges include experts from digital, creative and communications agencies, digital specialists and marketers from industry as well as healthcare professionals.

  • Moderna Announces Health Canada Approves its COVID

    Moderna Announces Health Canada Approves its COVID-19 Vaccine

    • 17 Sep 2021
    • Editor

    Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years of age and older.

  • Vifor Pharma and Travere Therapeutics announce lic

    Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

    • 17 Sep 2021
    • Editor

    Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-III clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease.

  • Dante Labs Announces Appointment of Global Legal E

    Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team

    • 17 Sep 2021
    • Editor

    Dante Labs, a global leader in genomics and precision medicine, today announced the appointment of Rachel Haverfield to the company’s leadership as General Counsel to drive the growth and scale of the business and opportunity. “We are so pleased to have Rachel joining Dante’s growing leadership of top talent in the industry,” said Andrea Riposati, CEO of Dante Labs.

  • PharmiWeb.Jobs Welcomes Oxford Global Resources NV

    PharmiWeb.Jobs Welcomes Oxford Global Resources NV

    • 16 Sep 2021
    • Nola Cadman

    Oxford is known for our unmatched ability to deliver “The Right Talent. Right Now.®” As a leading staffing and consulting company with offices across North America and Europe

  • Top Ten Pharmaceutical Companies in Europe

    Top Ten Pharmaceutical Companies in Europe

    • 16 Sep 2021
    • Lucy Walters

    In this article, we outline ten of the top pharmaceutical companies in Europe, based on 2020 sales reports and the scope of overall European operations.